Pramlintide acetate
DrugSubcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
Other names: Symlin
NCT Number: NCT00189514
This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Research Site, Chula Vista, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
Other names: Symlin
subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
Time frame: open ended
Time frame: open ended
Time frame: open ended
AstraZeneca
Industry
Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01249326
Atrophy, Bariatric Surgery
Clermont-Ferrand, France
View Trial DetailsNCT05715242
Behavior, Body Weight
Palo Alto, California, United States
View Trial DetailsNCT00687115
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT06978504
Body Weight, Body Weight Changes
Rio de Janeiro, Brazil
View Trial Details